Pharmacists, allow to dispense ivermectin without a prescription
Summary
HB278 would create a new process allowing pharmacists to dispense ivermectin without an individual prescription, so long as the dispensing occurs under a standing order approved by the State Board of Pharmacy and signed by a physician, physician assistant, or certified registered nurse practitioner. The bill limits this authority to adults 19 and older, and to minors only with written parental or guardian consent. It also requires the standing order to include a pharmacist risk-assessment protocol, adverse-event treatment plan, standardized patient information sheet, and documentation form.
The bill further bars health care providers and pharmacists from accepting incentives to encourage the public to use ivermectin, and it shields providers and pharmacists from professional discipline for dispensing under an approved standing order. The State Board of Pharmacy would be required to adopt rules to implement the act, and the bill specifies that it does not change the legal standards governing the practice of medicine or pharmacy or alter existing medical liability laws. The act would take effect October 1, 2025.
Impact
HB278 would amend Alabama prescription-drug and pharmacy practice rules by creating a standing-order pathway for ivermectin dispensing without a patient-specific prescription. It would affect pharmacists, physicians, physician assistants, certified registered nurse practitioners, and the State Board of Pharmacy by establishing new approval, documentation, counseling, and rulemaking requirements, while also limiting disciplinary exposure for compliant providers and pharmacists. The bill would not change broader malpractice standards, but it would create a specific statutory framework for ivermectin access and oversight.
Sentiment
Based on the available context, the bill appears to be moving through the House Health Committee without recorded opposition or vote history in the materials provided. The text suggests a policy goal of expanding access to ivermectin while adding procedural safeguards and professional protections, indicating support for pharmacist dispensing authority and provider discretion. Because there are no transcripts or votes, there is no documented committee debate to show broader agreement or disagreement.
Contention
The main points of potential contention are the bill’s expansion of ivermectin access without an individual prescription and the related professional-liability protections. Supporters are likely to emphasize access, pharmacist screening protocols, and shielding providers from discipline when acting under an approved standing order. Opponents or skeptics may focus on the drug’s controversial use, concerns about encouraging public use, the prohibition on incentives to promote ivermectin, and whether the bill could complicate pharmacy oversight or patient safety despite the required risk-assessment procedures.